MIBG scintigraphy in differential diagnosis of Parkinsonism: A meta-analysis

Clinical Autonomic Research

Volumn 22, Issue 1, 2012, Pages 43-55

  Treglia, Giorgio ^a   Cason, Ernesto ^b   Stefanelli, Antonella ^a   Cocciolillo, Fabrizio ^a   Di Giuda, Daniela ^a   Fagioli, Giorgio ^b   Giordano, Alessandro ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Differential diagnosis; Metaiodobenzylguanidine; MIBG; Parkinson's disease; Parkinsonism

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

BRAIN SCINTISCANNING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE SEVERITY; HUMAN; META ANALYSIS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PARKINSONISM; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

3-IODOBENZYLGUANIDINE; DIAGNOSIS, DIFFERENTIAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HEART; HUMANS; LEWY BODY DISEASE; PARKINSON DISEASE; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84858707220     PISSN: 09599851     EISSN: 16191560     Source Type: Journal    
DOI: 10.1007/s10286-011-0135-5     Document Type: Review

References (49)

1. Jost WH, Del Tredici K, Landvogt C, Braune S (2010) Importance of 123I-metaiodobenzylguanidine scintigraphy/single photon emission computed tomography for diagnosis and differential diagnostics of Parkinson syndromes. Neurodegener Dis 7:341-347
2. Treglia G, Cason E, Gabellini A, Giordano A, Fagioli G (2010) Recent developments in innervation imaging using iodine-123- metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 31:417-422
3. Yamashina S, Yamazaki J (2007) Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 34:939-950 (Pubitemid 46798959)
4. Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S (2008) Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 52:378-387
5. Rascol O, Schelosky L (2009) 123I-Metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 24(Suppl 2):732-741
6. Treglia G, Cason E (2010) Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. doi:10.1111/j.1552-6569.2010.00532.x (epub ahead of print)
7. Hishikawa N, Hashizume Y, Yoshida M, Sobue G (2003) Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 105:341-350 (Pubitemid 36798828)
8. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A (2006) Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 6:31
9. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH (1999) Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurology 53:1020-1025 (Pubitemid 29442118)
10. SalsoneM, Bagnato A, Novellino F, Cascini GL, Paglionico S, Cipullo S, MorelliM, Pugliese P, Nicoletti G,MessinaD,Condino F, Arabia G, Morgante L, Quattrone A (2009) Cardiac MIBG scintigraphy in primary progressive freezing gait. ParkinsonismRelat Disord 15:365-369
11. Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230-234
12. Druschky A, Hilz MJ, Platsch G, Radespiel-Tröger M, Druschky K, Kuwert T, Neundörfer B (2000) Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3-12 (Pubitemid 30227477)
13. Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, Takahashi A (2003) [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson's disease. Intern Med 42:127-128 (Pubitemid 36267681)
14. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 18:890-897 (Pubitemid 37021163)
15. Saiki S, Hirose G, Sakai K, Kataoka S, Hori A, Saiki M, Kaito M, Higashi K, Taki S, Kakeshita K, Fujino S, Miaki M (2004) Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 220:105-111 (Pubitemid 38622107)
16. Matsui H, Udaka F, Oda M, Kubori T, Nishinaka K, Kameyama M (2005) Metaiodobenzylguanidine (MIBG) scintigraphy at various parts of the body in Parkinson''s disease and multiple system atrophy. Auton Neurosci 119:56-60 (Pubitemid 40704699)
17. Lee PH, Kim JS, Shin DH, Yoon SN, Huh K (2006) Cardiac 123I-MIBG scintigraphy in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry 77:372-374
18. Shin DH, Lee PH, Bang OY, Joo IS, Huh K (2006) Clinical implications of cardiac-MIBG SPECT in the differentiation of Parkinsonian syndromes. J Clin Neurol 2:51-57
19. Lee PH, Yeo SH, Kim HJ, Youm HY (2006) Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord 21:1975-1977 (Pubitemid 44848949)
20. Lee PH, Yeo SH, Yong SW, Kim YJ (2007) Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced Parkinsonism. J Neurol Neurosurg Psychiatry 78:1250-1252
21. Yamashita F, Hirayama M, Nakamura T, Takamori M, Hori N, Uchida K, Hama T, Sobue G (2010) Pupillary autonomic dysfunction in multiple system atrophy and Parkinson's disease: an assessment by eye-drop tests. Clin Auton Res 20:191-197
22. Marini C, Bandettini di Poggio M, Pomposelli E, Marchese R, Nobili F, Morbelli SD, Villa G, Abbruzzese G, Sambuceti G (2010) Whole body and cardiac metaiodobenzylguanidine kinetics in Parkinson disease and multiple system atrophy: implications for the diagnostic role of imaging. Clin Nucl Med 35:311-316
23. Tateno F, Sakakibara R, Kishi M, Ogawa E, Terada H, Ogata T, Haruta H (2011) Sensitivity and specificity of metaiodobenzylguanidine (MIBG) myocardial accumulation in the diagnosis of Lewy body diseases in a movement disorder clinic. Parkinsonism Relat Disord. doi:10.1016/jparkreldis.2011.02.001 (epub ahead of print)
24. Fröhlich I, Pilloy W, Vaillant M, Diederich NJ (2010) Myocardial MIBG scintigraphy: a useful clinical tool? A retrospective study in 50 Parkinsonian patients. Neurol Sci 31:403-406
25. Ishibashi K, Saito Y, Murayama S, Kanemaru K, Oda K, Ishiwata K, Mizusawa H, Ishii K (2010) Validation of cardiac (123)IMIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging 37:3-11
26. Chung EJ, Lee WY, Yoon WT, Kim BJ, Lee GH (2009) MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 24:1650-1655
27. Novellino F, Arabia G, Bagnato A, Cascini GL, Salsone M, Nicoletti G, Messina D, Morelli M, Paglionico S, Giofrè L, Restuccia A, Torchia G, Condino F, Quattrone A (2009) Combined use of DAT-SPECT and cardiac MIBG scintigraphy in mixed tremors. Mov Disord 24:2242-2248
28. Sawada H, Oeda T, Yamamoto K, Kitagawa N, Mizuta E, Hosokawa R, Ohba M, Nishio R, Yamakawa K, Takeuchi H, Shimohama S, Takahashi R, Kawamura T (2009) Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease. Eur J Neurol 16:174-182
29. Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K (2008) 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31:717-723 (Pubitemid 351694259)
30. Nagamachi S, Wakamatsu H, Kiyohara S, Fujita S, Futami S, Tamura S, Nakazato M, Yamashita S, Arita H, Nishii R, Kawai K (2008) Usefulness of rCBF analysis in diagnosing Parkinson's disease: supplemental role with MIBG myocardial scintigraphy. Ann Nucl Med 22:557-564
31. Köllensperger M, Seppi K, Liener C, Boesch S, Heute D, Mair KJ, Mueller J, Sawires M, Scherfler C, Schocke MF, Donnemilier E, Virgolini I, Wenning GK, Poewe W (2007) Diffusion weighted imaging best discriminates PD from MSA-P: a comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22:1771-1776 (Pubitemid 47597601)
32. Kashihara K, Ohno M, Kawada S, Okumura Y (2006) Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 47:1099-1101 (Pubitemid 47544904)
33. Kim JS, Lee PH, Lee KS, Park JW, Kim YI, Chung YA, Kim SH, Kim SH, Kim J, Choi YY, Kim HT (2006) Cardiac [123I]metaiodobenzylguanidine scintigraphy for vascular Parkinsonism. Mov Disord 21:1990-1994 (Pubitemid 44848953)
34. Lee PH, Kim JW, Bang OY, Joo IS, Yoon SN, Huh K (2006) Cardiac 123I-MIBG scintigraphy in patients with essential tremor. Mov Disord 21:1235-1238 (Pubitemid 44336617)
35. Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y (2005) Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 76:249-251 (Pubitemid 40143717)
36. Reinhardt MJ, Jüngling FD, Krause TM, Braune S (2000) Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595-600 (Pubitemid 30262627)
37. Takatsu H, Nagashima K, Murase M, Fujiwara H, Nishida H, Matsuo H, Watanabe S, Satomi K (2000) Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 284:44-45 (Pubitemid 30445658)
38. Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, Sakajiri K, Tonami N (2000) Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 27:566-573 (Pubitemid 30262623)
39. Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H (1999) (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67:189-194 (Pubitemid 29326950)
40. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, Takashima H, Tsujihata M (1999) Loss of 123I-MIBG uptake by the heart in Parkinson's disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40:371-375 (Pubitemid 29120107)
41. Yoshita M (1998) Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60-67
42. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL (2008) Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 29:1147-1159 (Pubitemid 351844881)
43. King AE, Mintz J, Royall DR (2011) Meta-analysis of (123) I-MIBG cardiac scintigraphy for the diagnosis of Lewy bodyrelated disorders. Mov Disord. doi:10.1002/mds.23659
44. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE (1992) A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 13:513-521
45. Orimo S, Kanazawa T, Nakamura A, Uchihara T, Mori F, Kakita A, Wakabayashi K, Takahashi H (2007) Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113:81-86 (Pubitemid 44782932)
46. Sakata K, Iida K, Mochizuki N, Ito M, Nakaya Y (2009) Physiological changes in human cardiac sympathetic innervation and activity assessed by 123I-Metaiodobenzylguanidine (MIBG) imaging. Circ J 73:310-315
47. Braune S (2001) The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of Parkinsonian syndromes. Clin Auton Res 11:351-355
48. Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, Somsen GA, Unlu M, Verberne HJ, EANM Cardiovascular Committee; European Council of Nuclear Cardiology (2010) Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 37:1802-1812
49. Muxí A, Paredes P, Navales I, Valldeoriola F, Gaig C, Lomeña F, de la Cerda A, Solà O, Domenech B, Tolosa E, Pons F (2011) Diagnostic cutoff points for (123)I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson's disease. Eur J Nucl Med Mol Imaging 38:1139-1146